Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics is in a strong financial position with simplified cap table and significant cash reserve to support launch preparations, which are ongoing despite the delay caused by FDA’s Complete Response Letter. The company’s oxylanthanum carbonate has the potential to generate significant revenue in the hyperphosphatemia market, with peak risk-adjusted U.S. net sales projected to reach approximately $400 million in 2028. However, there are significant clinical and regulatory risks associated with the drug, as any negative outcomes could significantly impact the potential value of the program. The company’s success depends on successful execution and timely approval from the FDA, along with a successful launch in the market.

Bears say

Unicycive Therapeutics is facing significant regulatory and reimbursement risks, as the FDA has not yet inspected the third-party manufacturing site responsible for receiving a second Complete Response Letter for its phosphate binder OLC. This delay in approval has pushed back the potential launch of OLC, resulting in a decrease in our price target to $15 per share. Additionally, the company has a history of operating losses and may need to raise additional capital, which could dilute current shareholders. Furthermore, commercial adoption of OLC may be hindered by challenges in obtaining proper reimbursement and competition from other approved binders.

Unicycive Therapeutics (UNCY) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.